Fractyl Health's earnings call highlighted several positive developments, including a strengthened financial position, strategic focus on reducing cash burn, and promising data from the Revita program. However, the company also reported an increased net loss and highlighted dependence on future data readouts for continued success. The overall sentiment is cautiously optimistic, with significant potential contingent on upcoming results.

Company Guidance

During Fractyl Health's second-quarter 2025 earnings call, the company provided guidance on several key metrics and strategic initiatives. They reported a reduction in their cash burn rate from $25.4 million in Q1 to $19.8 million in Q2, following a strategic reprioritization. A $23 million public offering has positioned them to extend their cash runway through upcoming REMAIN-1 study milestones. Fractyl highlighted progress in their Revita program, reporting that recent data from a German study showed up to two years of weight maintenance benefits. Additionally, they expect to report 3-month randomized data from their REMAIN-1 midpoint cohort next month, which will be crucial for assessing Revita's efficacy in maintaining weight loss post-GLP-1 discontinuation. On the financial front, R&D expenses rose to $21.2 million from $16.8 million in the prior year, while their net loss increased to $27.9 million. The company expects its current cash position to support operations into 2026, aligning with key data readouts and a potential FDA application for Revita.

Strengthened Financial Position

Fractyl Health completed a $23 million underwritten public offering of common stock, led by several leading healthcare investors, which extends the company’s cash runway through key upcoming data readouts.

Reduced Cash Burn

The company reduced its cash burn rate from $25.4 million in Q1 to $19.8 million in Q2 by winding down spend on noncritical programs.

Positive Data from Revita

New data from the German real-world registry study showed up to two years of benefit in weight maintenance and blood sugar control following a single Revita treatment.

Revita's Market Potential

Revita could be positioned as a straightforward, one-time intervention for obesity, akin to LASIK, with substantial interest from GI physicians and potential for significant procedure volumes upon FDA approval.

Rejuva Program Advancements

Rejuva has completed preclinical efficacy, toxicity, and biodistribution studies, with CMC manufacturing nearly complete and agreement reached with regulators on the design of the forthcoming clinical study.

Fractyl Health, Inc. (GUTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GUTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.34 / -	-0.43	―	―	―
Aug 12, 2025	2025 (Q2)	-0.36 / -0.56	-0.28	-100.00% (-0.28)	―
May 13, 2025	2025 (Q1)	-0.48 / -0.47	0	―	―
Mar 03, 2025	2024 (Q4)	-0.43 / -0.52	-11.18	95.35% (+10.66)	―
Nov 12, 2024	2024 (Q3)	-0.50 / -0.43	-0.62	30.65% (+0.19)	―
Aug 14, 2024	2024 (Q2)	-0.46 / -0.28	―	―	―
May 13, 2024	2024 (Q1)	- / -	-0.338	―	―
Apr 01, 2024	2023 (Q4)	-0.30 / 0.00	-0.338	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GUTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$0.98	$1.01	+3.06%
May 13, 2025	$1.77	$1.54	-12.99%
Mar 03, 2025	$1.56	$1.50	-3.85%
Nov 12, 2024	$2.43	$2.37	-2.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fractyl Health, Inc. (GUTS) report earnings?

Fractyl Health, Inc. (GUTS) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is Fractyl Health, Inc. (GUTS) earnings time?

Fractyl Health, Inc. (GUTS) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GUTS EPS forecast?

GUTS EPS forecast for the fiscal quarter 2025 (Q3) is -0.34.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing